Silverarc Capital Management LLC increased its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 116.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 152,395 shares of the company's stock after acquiring an additional 81,879 shares during the quarter. Silverarc Capital Management LLC owned about 0.27% of Structure Therapeutics worth $4,133,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of GPCR. Geode Capital Management LLC grew its position in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after purchasing an additional 312 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its stake in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares during the period. LPL Financial LLC grew its holdings in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Structure Therapeutics by 12.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares during the period. Finally, Money Concepts Capital Corp lifted its holdings in shares of Structure Therapeutics by 4.2% during the fourth quarter. Money Concepts Capital Corp now owns 21,031 shares of the company's stock worth $570,000 after buying an additional 848 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.
Wall Street Analysts Forecast Growth
GPCR has been the topic of a number of research reports. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Tuesday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and a consensus target price of $81.29.
Check Out Our Latest Research Report on GPCR
Structure Therapeutics Stock Performance
Shares of NASDAQ:GPCR traded up $0.09 during midday trading on Friday, reaching $23.74. 731,787 shares of the company's stock were exchanged, compared to its average volume of 913,938. The company's 50 day simple moving average is $20.14 and its two-hundred day simple moving average is $27.99. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The firm has a market capitalization of $1.36 billion, a PE ratio of -32.08 and a beta of -1.35.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.
About Structure Therapeutics
(
Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
